Share Price and Basic Stock Data
Last Updated: January 30, 2026, 10:27 pm
| PEG Ratio | -2.65 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Godavari Drugs Ltd operates in the pharmaceuticals sector, primarily focusing on the production of active pharmaceutical ingredients (APIs). The company’s market capitalization stood at ₹67.0 Cr, and the stock price was reported at ₹89.0. Over recent periods, Godavari’s revenue trajectory has shown fluctuations. For the fiscal year ending March 2023, sales were recorded at ₹160 Cr, a slight decline from ₹161 Cr in the previous fiscal year. The trailing twelve months (TTM) revenue is reported at ₹106 Cr, suggesting a continued downward trend. Quarterly sales figures indicate a peak in December 2023 at ₹43.11 Cr, followed by a decline in subsequent quarters, raising concerns about demand stability. The company’s operational performance, reflected in Operating Profit Margin (OPM), reported at 7.50%, remains below the industry average, indicating potential challenges in cost management and pricing strategy.
Profitability and Efficiency Metrics
Godavari Drugs has displayed mixed profitability metrics. The net profit for the last fiscal year was reported at ₹4 Cr, translating to a net profit margin of 3.86%, which is on the lower end compared to typical industry standards. The company’s earnings per share (EPS) stood at ₹5.82 for the fiscal year ending March 2025, down from ₹7.37 in the previous year. Return on Equity (ROE) is reported at 10.6%, and Return on Capital Employed (ROCE) at 10.1%, both of which are modest compared to industry benchmarks. Efficiency ratios reveal a cash conversion cycle (CCC) of 133 days, indicating longer durations for converting investments into cash flows. The interest coverage ratio (ICR) of 2.71x suggests that while the company can cover its interest obligations, it does not have a substantial buffer, which may limit financial flexibility in adverse conditions.
Balance Sheet Strength and Financial Ratios
The balance sheet of Godavari Drugs reflects a cautious financial structure, with total borrowings reported at ₹74 Cr against reserves of ₹38 Cr. This indicates a relatively high debt-to-equity ratio of 1.42, which is concerning, as it suggests that the company is heavily reliant on debt financing. Current and quick ratios stood at 1.08x and 0.69x, respectively, indicating that while short-term obligations can be met, liquidity may be tight. The book value per share increased to ₹57.56, reflecting growth in shareholder equity. However, the enterprise value (EV) of ₹125.12 Cr against net operating revenue highlights a valuation that may be under pressure given the recent sales performance. Despite these challenges, the company’s interest coverage ratio of 2.71x shows that it can manage its interest expenses, albeit with limited headroom.
Shareholding Pattern and Investor Confidence
The shareholding structure of Godavari Drugs indicates a significant promoter holding of 52.61%, which reflects a strong insider commitment to the company’s future. However, the presence of Foreign Institutional Investors (FIIs) is notably absent, while Domestic Institutional Investors (DIIs) hold a mere 0.50%. Public shareholding is substantial at 46.90%, with the number of shareholders increasing to 7,720, indicating growing retail interest. This concentration of ownership among promoters may raise concerns about governance and the alignment of interests with minority shareholders. The stability in promoter holdings over the reporting periods suggests confidence in the company’s long-term strategy. However, the low institutional participation may impact liquidity and perceived stability in the stock, warranting attention from potential investors.
Outlook, Risks, and Final Insight
Looking ahead, Godavari Drugs faces both opportunities and challenges. The recent uptick in quarterly sales to ₹43.11 Cr in December 2023 could indicate potential recovery, but the overall declining sales trend raises concerns about sustainability. Risks include high leverage, with borrowings exceeding reserves, which could strain financial health during downturns. Additionally, the company’s ability to improve profitability metrics will be critical, especially in a competitive environment where margins are under pressure. Strengths include a solid base of promoter ownership and a manageable interest coverage ratio, providing some stability. Investors should monitor future quarterly results closely, particularly for indications of a turnaround in revenue trends and improvements in operational efficiencies. Strategic focus on cost management and debt reduction will be essential for long-term viability.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 121 Cr. | 96.2 | 197/84.3 | 26.8 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 3,504 Cr. | 323 | 479/192 | 72.6 | 24.3 | 0.21 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.1 Cr. | 46.0 | 82.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 71.3 Cr. | 48.7 | 49.3/17.0 | 170 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 19,596.58 Cr | 1,092.82 | 46.83 | 202.32 | 0.38% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 40.55 | 39.16 | 37.37 | 35.42 | 39.54 | 43.11 | 38.64 | 32.21 | 26.09 | 29.55 | 25.50 | 23.81 | 26.65 |
| Expenses | 37.98 | 36.89 | 34.69 | 33.17 | 36.47 | 39.59 | 34.17 | 28.98 | 23.19 | 26.97 | 22.39 | 20.91 | 24.65 |
| Operating Profit | 2.57 | 2.27 | 2.68 | 2.25 | 3.07 | 3.52 | 4.47 | 3.23 | 2.90 | 2.58 | 3.11 | 2.90 | 2.00 |
| OPM % | 6.34% | 5.80% | 7.17% | 6.35% | 7.76% | 8.17% | 11.57% | 10.03% | 11.12% | 8.73% | 12.20% | 12.18% | 7.50% |
| Other Income | 0.13 | 0.30 | 0.39 | 0.45 | 0.00 | -0.01 | 0.08 | 0.77 | 0.01 | 0.10 | 0.11 | 0.01 | 0.64 |
| Interest | 1.06 | 1.10 | 1.03 | 1.11 | 1.30 | 1.27 | 1.23 | 1.44 | 1.08 | 1.11 | 1.11 | 1.00 | 0.91 |
| Depreciation | 0.47 | 0.51 | 0.50 | 0.47 | 0.49 | 0.50 | 0.53 | 0.55 | 0.58 | 0.64 | 0.67 | 0.60 | 0.60 |
| Profit before tax | 1.17 | 0.96 | 1.54 | 1.12 | 1.28 | 1.74 | 2.79 | 2.01 | 1.25 | 0.93 | 1.44 | 1.31 | 1.13 |
| Tax % | 26.50% | 30.21% | 13.64% | 27.68% | 32.81% | 29.89% | 4.66% | 18.91% | 12.80% | 16.13% | 38.19% | 19.85% | 10.62% |
| Net Profit | 0.86 | 0.67 | 1.33 | 0.81 | 0.86 | 1.22 | 2.66 | 1.63 | 1.09 | 0.77 | 0.89 | 1.04 | 1.00 |
| EPS in Rs | 1.14 | 0.89 | 1.77 | 1.08 | 1.14 | 1.62 | 3.53 | 2.16 | 1.45 | 1.02 | 1.18 | 1.38 | 1.33 |
Last Updated: January 7, 2026, 4:34 am
Below is a detailed analysis of the quarterly data for Godavari Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 26.65 Cr.. The value appears strong and on an upward trend. It has increased from 23.81 Cr. (Jun 2025) to 26.65 Cr., marking an increase of 2.84 Cr..
- For Expenses, as of Sep 2025, the value is 24.65 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 20.91 Cr. (Jun 2025) to 24.65 Cr., marking an increase of 3.74 Cr..
- For Operating Profit, as of Sep 2025, the value is 2.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.90 Cr. (Jun 2025) to 2.00 Cr., marking a decrease of 0.90 Cr..
- For OPM %, as of Sep 2025, the value is 7.50%. The value appears to be declining and may need further review. It has decreased from 12.18% (Jun 2025) to 7.50%, marking a decrease of 4.68%.
- For Other Income, as of Sep 2025, the value is 0.64 Cr.. The value appears strong and on an upward trend. It has increased from 0.01 Cr. (Jun 2025) to 0.64 Cr., marking an increase of 0.63 Cr..
- For Interest, as of Sep 2025, the value is 0.91 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.00 Cr. (Jun 2025) to 0.91 Cr., marking a decrease of 0.09 Cr..
- For Depreciation, as of Sep 2025, the value is 0.60 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.60 Cr..
- For Profit before tax, as of Sep 2025, the value is 1.13 Cr.. The value appears to be declining and may need further review. It has decreased from 1.31 Cr. (Jun 2025) to 1.13 Cr., marking a decrease of 0.18 Cr..
- For Tax %, as of Sep 2025, the value is 10.62%. The value appears to be improving (decreasing) as expected. It has decreased from 19.85% (Jun 2025) to 10.62%, marking a decrease of 9.23%.
- For Net Profit, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.04 Cr. (Jun 2025) to 1.00 Cr., marking a decrease of 0.04 Cr..
- For EPS in Rs, as of Sep 2025, the value is 1.33. The value appears to be declining and may need further review. It has decreased from 1.38 (Jun 2025) to 1.33, marking a decrease of 0.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 3:38 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 9 | 55 | 71 | 76 | 64 | 84 | 96 | 123 | 161 | 160 | 157 | 113 | 106 |
| Expenses | 8 | 49 | 67 | 70 | 60 | 78 | 90 | 113 | 150 | 150 | 143 | 102 | 95 |
| Operating Profit | 2 | 6 | 4 | 5 | 4 | 5 | 6 | 10 | 11 | 10 | 13 | 12 | 11 |
| OPM % | 20% | 11% | 6% | 7% | 6% | 7% | 6% | 8% | 7% | 6% | 8% | 10% | 10% |
| Other Income | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Interest | 0 | 1 | 2 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 5 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before tax | 1 | 5 | 2 | 3 | 1 | 2 | 2 | 6 | 7 | 5 | 7 | 6 | 5 |
| Tax % | -121% | 23% | 38% | 33% | 37% | 31% | 13% | 28% | 25% | 23% | 20% | 22% | |
| Net Profit | 2 | 4 | 1 | 2 | 1 | 1 | 2 | 4 | 5 | 4 | 6 | 4 | 4 |
| EPS in Rs | 2.06 | 4.85 | 1.79 | 2.40 | 1.10 | 1.61 | 2.66 | 5.48 | 6.97 | 5.03 | 7.37 | 5.82 | 4.91 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 100.00% | -75.00% | 100.00% | -50.00% | 0.00% | 100.00% | 100.00% | 25.00% | -20.00% | 50.00% | -33.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -175.00% | 175.00% | -150.00% | 50.00% | 100.00% | 0.00% | -75.00% | -45.00% | 70.00% | -83.33% |
Godavari Drugs Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 8% |
| 5 Years: | 3% |
| 3 Years: | -11% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | 17% |
| 3 Years: | -6% |
| TTM: | -41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 4% |
| 5 Years: | 17% |
| 3 Years: | 7% |
| 1 Year: | -41% |
| Return on Equity | |
|---|---|
| 10 Years: | 13% |
| 5 Years: | 15% |
| 3 Years: | 13% |
| Last Year: | 11% |
Last Updated: September 5, 2025, 3:36 pm
Balance Sheet
Last Updated: January 7, 2026, 5:33 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 |
| Reserves | 2 | 6 | 7 | 9 | 10 | 11 | 13 | 17 | 22 | 26 | 31 | 36 | 38 |
| Borrowings | 2 | 8 | 16 | 16 | 19 | 22 | 28 | 30 | 23 | 36 | 58 | 64 | 74 |
| Other Liabilities | 3 | 13 | 21 | 24 | 27 | 33 | 36 | 36 | 49 | 52 | 38 | 35 | 43 |
| Total Liabilities | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 162 |
| Fixed Assets | 8 | 7 | 9 | 13 | 15 | 15 | 14 | 22 | 26 | 25 | 27 | 33 | 31 |
| CWIP | -0 | 0 | 1 | 0 | 1 | 2 | 9 | 1 | 0 | 9 | 18 | 30 | 41 |
| Investments | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Other Assets | 7 | 27 | 41 | 43 | 47 | 57 | 61 | 68 | 75 | 87 | 90 | 81 | 90 |
| Total Assets | 15 | 35 | 51 | 56 | 63 | 74 | 84 | 91 | 101 | 121 | 135 | 143 | 162 |
Below is a detailed analysis of the balance sheet data for Godavari Drugs Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 8.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 8.00 Cr..
- For Reserves, as of Sep 2025, the value is 38.00 Cr.. The value appears strong and on an upward trend. It has increased from 36.00 Cr. (Mar 2025) to 38.00 Cr., marking an increase of 2.00 Cr..
- For Borrowings, as of Sep 2025, the value is 74.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 64.00 Cr. (Mar 2025) to 74.00 Cr., marking an increase of 10.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 43.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 35.00 Cr. (Mar 2025) to 43.00 Cr., marking an increase of 8.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 162.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 143.00 Cr. (Mar 2025) to 162.00 Cr., marking an increase of 19.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 31.00 Cr.. The value appears to be declining and may need further review. It has decreased from 33.00 Cr. (Mar 2025) to 31.00 Cr., marking a decrease of 2.00 Cr..
- For CWIP, as of Sep 2025, the value is 41.00 Cr.. The value appears strong and on an upward trend. It has increased from 30.00 Cr. (Mar 2025) to 41.00 Cr., marking an increase of 11.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 90.00 Cr.. The value appears strong and on an upward trend. It has increased from 81.00 Cr. (Mar 2025) to 90.00 Cr., marking an increase of 9.00 Cr..
- For Total Assets, as of Sep 2025, the value is 162.00 Cr.. The value appears strong and on an upward trend. It has increased from 143.00 Cr. (Mar 2025) to 162.00 Cr., marking an increase of 19.00 Cr..
However, the Borrowings (74.00 Cr.) are higher than the Reserves (38.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 0.00 | -2.00 | -12.00 | -11.00 | -15.00 | -17.00 | -22.00 | -20.00 | -12.00 | -26.00 | -45.00 | -52.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 20 | 87 | 126 | 117 | 152 | 148 | 137 | 134 | 126 | 132 | 138 | 136 |
| Inventory Days | 973 | 84 | 67 | 70 | 100 | 93 | 84 | 55 | 28 | 57 | 62 | 125 |
| Days Payable | 179 | 79 | 108 | 124 | 171 | 171 | 144 | 112 | 121 | 132 | 96 | 128 |
| Cash Conversion Cycle | 814 | 92 | 85 | 63 | 81 | 70 | 78 | 78 | 33 | 58 | 105 | 133 |
| Working Capital Days | 120 | 63 | 44 | 40 | 47 | 38 | 31 | 46 | 32 | 23 | 9 | 11 |
| ROCE % | 8% | 32% | 16% | 17% | 11% | 12% | 12% | 18% | 18% | 14% | 14% | 10% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 |
| Diluted EPS (Rs.) | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 |
| Cash EPS (Rs.) | 9.07 | 10.02 | 7.61 | 9.22 | 7.11 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 |
| Revenue From Operations / Share (Rs.) | 150.52 | 208.10 | 211.97 | 213.94 | 162.90 |
| PBDIT / Share (Rs.) | 17.00 | 18.49 | 14.04 | 15.36 | 13.59 |
| PBIT / Share (Rs.) | 13.75 | 15.84 | 11.46 | 13.11 | 11.97 |
| PBT / Share (Rs.) | 7.47 | 9.19 | 6.55 | 9.32 | 7.58 |
| Net Profit / Share (Rs.) | 5.82 | 7.37 | 5.03 | 6.96 | 5.48 |
| PBDIT Margin (%) | 11.29 | 8.88 | 6.62 | 7.17 | 8.34 |
| PBIT Margin (%) | 9.13 | 7.61 | 5.40 | 6.12 | 7.34 |
| PBT Margin (%) | 4.96 | 4.41 | 3.09 | 4.35 | 4.65 |
| Net Profit Margin (%) | 3.86 | 3.54 | 2.37 | 3.25 | 3.36 |
| Return on Networth / Equity (%) | 10.10 | 14.24 | 11.32 | 17.70 | 16.92 |
| Return on Capital Employeed (%) | 14.79 | 22.60 | 18.08 | 22.61 | 22.18 |
| Return On Assets (%) | 3.06 | 4.11 | 3.11 | 5.17 | 4.52 |
| Long Term Debt / Equity (X) | 0.55 | 0.28 | 0.35 | 0.39 | 0.59 |
| Total Debt / Equity (X) | 1.42 | 1.43 | 1.00 | 0.68 | 1.15 |
| Asset Turnover Ratio (%) | 0.81 | 1.22 | 1.43 | 1.67 | 1.40 |
| Current Ratio (X) | 1.08 | 1.08 | 1.18 | 1.29 | 1.34 |
| Quick Ratio (X) | 0.69 | 0.82 | 0.91 | 1.11 | 1.05 |
| Inventory Turnover Ratio (X) | 4.67 | 6.02 | 9.22 | 10.37 | 5.81 |
| Interest Coverage Ratio (X) | 2.71 | 2.83 | 2.69 | 4.06 | 3.09 |
| Interest Coverage Ratio (Post Tax) (X) | 1.93 | 2.15 | 1.91 | 2.84 | 2.25 |
| Enterprise Value (Cr.) | 125.12 | 123.00 | 87.45 | 67.32 | 60.89 |
| EV / Net Operating Revenue (X) | 1.10 | 0.78 | 0.54 | 0.41 | 0.49 |
| EV / EBITDA (X) | 9.77 | 8.83 | 8.27 | 5.82 | 5.95 |
| MarketCap / Net Operating Revenue (X) | 0.58 | 0.44 | 0.35 | 0.30 | 0.28 |
| Price / BV (X) | 1.52 | 1.80 | 1.71 | 1.66 | 1.41 |
| Price / Net Operating Revenue (X) | 0.58 | 0.44 | 0.35 | 0.30 | 0.28 |
| EarningsYield | 0.06 | 0.07 | 0.06 | 0.10 | 0.11 |
After reviewing the key financial ratios for Godavari Drugs Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
- For Diluted EPS (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
- For Cash EPS (Rs.), as of Mar 25, the value is 9.07. This value is within the healthy range. It has decreased from 10.02 (Mar 24) to 9.07, marking a decrease of 0.95.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 57.56. It has increased from 51.74 (Mar 24) to 57.56, marking an increase of 5.82.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 150.52. It has decreased from 208.10 (Mar 24) to 150.52, marking a decrease of 57.58.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 17.00. This value is within the healthy range. It has decreased from 18.49 (Mar 24) to 17.00, marking a decrease of 1.49.
- For PBIT / Share (Rs.), as of Mar 25, the value is 13.75. This value is within the healthy range. It has decreased from 15.84 (Mar 24) to 13.75, marking a decrease of 2.09.
- For PBT / Share (Rs.), as of Mar 25, the value is 7.47. This value is within the healthy range. It has decreased from 9.19 (Mar 24) to 7.47, marking a decrease of 1.72.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 5.82. This value is within the healthy range. It has decreased from 7.37 (Mar 24) to 5.82, marking a decrease of 1.55.
- For PBDIT Margin (%), as of Mar 25, the value is 11.29. This value is within the healthy range. It has increased from 8.88 (Mar 24) to 11.29, marking an increase of 2.41.
- For PBIT Margin (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 7.61 (Mar 24) to 9.13, marking an increase of 1.52.
- For PBT Margin (%), as of Mar 25, the value is 4.96. This value is below the healthy minimum of 10. It has increased from 4.41 (Mar 24) to 4.96, marking an increase of 0.55.
- For Net Profit Margin (%), as of Mar 25, the value is 3.86. This value is below the healthy minimum of 5. It has increased from 3.54 (Mar 24) to 3.86, marking an increase of 0.32.
- For Return on Networth / Equity (%), as of Mar 25, the value is 10.10. This value is below the healthy minimum of 15. It has decreased from 14.24 (Mar 24) to 10.10, marking a decrease of 4.14.
- For Return on Capital Employeed (%), as of Mar 25, the value is 14.79. This value is within the healthy range. It has decreased from 22.60 (Mar 24) to 14.79, marking a decrease of 7.81.
- For Return On Assets (%), as of Mar 25, the value is 3.06. This value is below the healthy minimum of 5. It has decreased from 4.11 (Mar 24) to 3.06, marking a decrease of 1.05.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.55. This value is within the healthy range. It has increased from 0.28 (Mar 24) to 0.55, marking an increase of 0.27.
- For Total Debt / Equity (X), as of Mar 25, the value is 1.42. This value exceeds the healthy maximum of 1. It has decreased from 1.43 (Mar 24) to 1.42, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.81. It has decreased from 1.22 (Mar 24) to 0.81, marking a decrease of 0.41.
- For Current Ratio (X), as of Mar 25, the value is 1.08. This value is below the healthy minimum of 1.5. There is no change compared to the previous period (Mar 24) which recorded 1.08.
- For Quick Ratio (X), as of Mar 25, the value is 0.69. This value is below the healthy minimum of 1. It has decreased from 0.82 (Mar 24) to 0.69, marking a decrease of 0.13.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 4.67. This value is within the healthy range. It has decreased from 6.02 (Mar 24) to 4.67, marking a decrease of 1.35.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.71. This value is below the healthy minimum of 3. It has decreased from 2.83 (Mar 24) to 2.71, marking a decrease of 0.12.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.93. This value is below the healthy minimum of 3. It has decreased from 2.15 (Mar 24) to 1.93, marking a decrease of 0.22.
- For Enterprise Value (Cr.), as of Mar 25, the value is 125.12. It has increased from 123.00 (Mar 24) to 125.12, marking an increase of 2.12.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.10. This value is within the healthy range. It has increased from 0.78 (Mar 24) to 1.10, marking an increase of 0.32.
- For EV / EBITDA (X), as of Mar 25, the value is 9.77. This value is within the healthy range. It has increased from 8.83 (Mar 24) to 9.77, marking an increase of 0.94.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
- For Price / BV (X), as of Mar 25, the value is 1.52. This value is within the healthy range. It has decreased from 1.80 (Mar 24) to 1.52, marking a decrease of 0.28.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.58. This value is below the healthy minimum of 1. It has increased from 0.44 (Mar 24) to 0.58, marking an increase of 0.14.
- For EarningsYield, as of Mar 25, the value is 0.06. This value is below the healthy minimum of 5. It has decreased from 0.07 (Mar 24) to 0.06, marking a decrease of 0.01.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Godavari Drugs Ltd:
- Net Profit Margin: 3.86%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 14.79% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 10.1% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.93
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 17.9 (Industry average Stock P/E: 46.83)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 1.42
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 3.86%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 1-8-303/34, Secunderabad Telangana 500003 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Ghanshyam Jaju | Chairman |
| Mr. Mukund Kakani | Managing Director |
| Mr. Mohit Jaju | WholeTime Director & CFO |
| Mr. Mahendra Bhalerao | Ind. Non-Executive Director |
| Mr. Dinesh Udpa | Ind. Non-Executive Director |
| Mrs. Shilpa Bung | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Godavari Drugs Ltd?
Godavari Drugs Ltd's intrinsic value (as of 30 January 2026) is ₹87.04 which is 1.20% lower the current market price of ₹88.10, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹66.3 Cr. market cap, FY2025-2026 high/low of ₹115/69.7, reserves of ₹38 Cr, and liabilities of ₹162 Cr.
What is the Market Cap of Godavari Drugs Ltd?
The Market Cap of Godavari Drugs Ltd is 66.3 Cr..
What is the current Stock Price of Godavari Drugs Ltd as on 30 January 2026?
The current stock price of Godavari Drugs Ltd as on 30 January 2026 is ₹88.1.
What is the High / Low of Godavari Drugs Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Godavari Drugs Ltd stocks is ₹115/69.7.
What is the Stock P/E of Godavari Drugs Ltd?
The Stock P/E of Godavari Drugs Ltd is 17.9.
What is the Book Value of Godavari Drugs Ltd?
The Book Value of Godavari Drugs Ltd is 60.3.
What is the Dividend Yield of Godavari Drugs Ltd?
The Dividend Yield of Godavari Drugs Ltd is 0.00 %.
What is the ROCE of Godavari Drugs Ltd?
The ROCE of Godavari Drugs Ltd is 10.1 %.
What is the ROE of Godavari Drugs Ltd?
The ROE of Godavari Drugs Ltd is 10.6 %.
What is the Face Value of Godavari Drugs Ltd?
The Face Value of Godavari Drugs Ltd is 10.0.